CY1117234T1 - Μεθοδος προσδιορισμου της ευαισθησιας ασθενους στη θεραπεια αναστολης της τελομερασης - Google Patents

Μεθοδος προσδιορισμου της ευαισθησιας ασθενους στη θεραπεια αναστολης της τελομερασης

Info

Publication number
CY1117234T1
CY1117234T1 CY20161100171T CY161100171T CY1117234T1 CY 1117234 T1 CY1117234 T1 CY 1117234T1 CY 20161100171 T CY20161100171 T CY 20161100171T CY 161100171 T CY161100171 T CY 161100171T CY 1117234 T1 CY1117234 T1 CY 1117234T1
Authority
CY
Cyprus
Prior art keywords
sensitivity
help
treatment
determining
determining patients
Prior art date
Application number
CY20161100171T
Other languages
English (en)
Inventor
Calvin B Harley
Laurence Elias
Jennifer Smith
Mark J Ratain
Fabio Benedetti
Original Assignee
Geron Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corporation filed Critical Geron Corporation
Publication of CY1117234T1 publication Critical patent/CY1117234T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)

Abstract

Η εφεύρεση παρέχει μεθόδους για τον προσδιορισμό της ευαισθησίας ασθενών με καρκίνο, στην ανάπτυξη ανεπιθύμητων αντιδράσεων, εάν υποβληθούν σε θεραπεία με φάρμακο αναστολέα της τελομεράσης, με μέτρηση του μήκους του τελομερούς στα κατάλληλα κύτταρα του ασθενούς, πριν την έναρξη της θεραπείας με αναστολέα.
CY20161100171T 2008-10-17 2016-03-01 Μεθοδος προσδιορισμου της ευαισθησιας ασθενους στη θεραπεια αναστολης της τελομερασης CY1117234T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10649108P 2008-10-17 2008-10-17
EP09821131.1A EP2342360B1 (en) 2008-10-17 2009-10-13 Method for identification of sensitivity of a patient to telomerase inhibition therapy

Publications (1)

Publication Number Publication Date
CY1117234T1 true CY1117234T1 (el) 2017-04-05

Family

ID=42106854

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161100171T CY1117234T1 (el) 2008-10-17 2016-03-01 Μεθοδος προσδιορισμου της ευαισθησιας ασθενους στη θεραπεια αναστολης της τελομερασης
CY20171101163T CY1119653T1 (el) 2008-10-17 2017-11-07 Μεθοδος για ταυτοποιηση της ευαισθησιας ενος ασθενους σε θεραπεια αναστολης της τελομερασης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20171101163T CY1119653T1 (el) 2008-10-17 2017-11-07 Μεθοδος για ταυτοποιηση της ευαισθησιας ενος ασθενους σε θεραπεια αναστολης της τελομερασης

Country Status (15)

Country Link
US (8) US8877723B2 (el)
EP (4) EP3719139B1 (el)
CY (2) CY1117234T1 (el)
DK (2) DK2342360T3 (el)
ES (4) ES2566338T3 (el)
HK (2) HK1224341A1 (el)
HR (2) HRP20160067T1 (el)
HU (2) HUE027213T2 (el)
LT (1) LT3029154T (el)
NO (1) NO3029154T3 (el)
PL (2) PL3029154T3 (el)
PT (3) PT3029154T (el)
SI (2) SI3029154T1 (el)
SM (1) SMT201600087B (el)
WO (1) WO2010045245A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
SG11201504209YA (en) * 2012-11-30 2015-06-29 Geron Corp Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
CN109662968B (zh) * 2017-10-13 2021-05-18 上海奥奇医药科技有限公司 含A-失碳-5α雄甾烷化合物的升白制剂及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5776679A (en) 1994-07-07 1998-07-07 Geron Corporation Assays for the DNA component of human telomerase
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5741677A (en) 1995-06-07 1998-04-21 Geron Corporation Methods for measuring telomere length
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
EP0870055B1 (en) 1995-10-12 2007-05-16 LANSDORP, Peter, M. Method for detecting multiple copies of a repeat sequence in a nucleic acid molecule
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
WO1998028442A1 (en) 1996-12-20 1998-07-02 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
US6156763A (en) * 1998-02-04 2000-12-05 Board Of Regents, The University Of Texas System Inhibition of human telomerase by a g-quadruplex-interaction compound
US6995145B1 (en) * 1999-06-04 2006-02-07 Au Jessie L-S Methods and compositions for modulating drug activity through telomere damage
EP1992634A1 (en) 1999-09-10 2008-11-19 Geron Corporation Oligonucleotide n3'- p5' thiophosphoramidates: their synthesis and use
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
CN101711868A (zh) 2000-05-19 2010-05-26 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
US9777312B2 (en) * 2001-06-30 2017-10-03 Enzo Life Sciences, Inc. Dual polarity analysis of nucleic acids
US7695904B2 (en) 2002-01-31 2010-04-13 University Of Utah Research Foundation Reducing non-target nucleic acid dependent amplifications: amplifying repetitive nucleic acid sequences
US20040234961A1 (en) 2002-04-22 2004-11-25 Fordyce Colleen A. Telomere length determination and applications
US9169516B2 (en) 2003-01-24 2015-10-27 University Of Utah Research Foundation Methods of predicting mortality risk by determining telomere length
BRPI0414222B8 (pt) 2003-09-09 2021-05-25 Geron Corp compostos oligonucleotídeos modificados para inibição da telomerase, métodos, composição farmacêutica e usos relacionados
ME02933B (me) 2004-07-02 2018-04-20 Geron Corp Sinteza zaštićenih 3'-amino nukleozionih monomera
DE102005024834B3 (de) 2005-05-31 2007-01-04 Lucas Automotive Gmbh Verfahren und System zur Steuerung einer Kraftfahrzeug-Feststellbremse während eines Halts
CA2615374A1 (en) * 2005-07-18 2007-01-25 Ernest Kun Kun Treatment of cancer
AU2006321975A1 (en) * 2005-12-06 2007-06-14 Wyeth Interleukin-11 compositions and methods of use
US9155753B2 (en) * 2007-03-09 2015-10-13 Geron Corporation Treatment of carcinomas with a combination of EGF-pathway and telomerase inhibitors
WO2008119027A2 (en) 2007-03-27 2008-10-02 The Johns Hopkins University Genetic testing of telomere-associated genes in dyskeratosis congenita and related disorders
US20090142770A1 (en) 2007-12-04 2009-06-04 Geron Corporation Hair Follicle Pharmacodynamic Assay for Telomerase Activity
US20090298709A1 (en) 2008-05-28 2009-12-03 Affymetrix, Inc. Assays for determining telomere length and repeated sequence copy number
US20110207128A1 (en) 2010-02-16 2011-08-25 Cawthon Richard M Methods and kits for determining biological age and longevity based on gene expression profiles
SG11201504209YA (en) 2012-11-30 2015-06-29 Geron Corp Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors

Also Published As

Publication number Publication date
EP2342360B1 (en) 2016-01-06
EP3330383B1 (en) 2020-02-12
US20230114322A1 (en) 2023-04-13
SI3029154T1 (en) 2018-02-28
US20190382829A1 (en) 2019-12-19
PL3029154T3 (pl) 2018-03-30
US20150152488A1 (en) 2015-06-04
US20220325327A1 (en) 2022-10-13
EP2342360A1 (en) 2011-07-13
PL2342360T3 (pl) 2016-06-30
HRP20160067T1 (hr) 2016-03-25
PT3029154T (pt) 2017-12-06
LT3029154T (lt) 2017-12-27
HUE037447T2 (hu) 2018-08-28
ES2645872T3 (es) 2017-12-11
ES2566338T3 (es) 2016-04-12
WO2010045245A1 (en) 2010-04-22
US20240318232A1 (en) 2024-09-26
US20170298421A1 (en) 2017-10-19
ES2939509T3 (es) 2023-04-24
CY1119653T1 (el) 2018-04-04
DK3029154T3 (en) 2017-12-11
US20110263685A1 (en) 2011-10-27
EP3719139A1 (en) 2020-10-07
HK1256479A1 (zh) 2019-09-27
HUE027213T2 (en) 2016-10-28
US8877723B2 (en) 2014-11-04
SI2342360T1 (sl) 2016-04-29
NO3029154T3 (el) 2018-03-03
EP3719139B1 (en) 2022-11-30
US20210269861A1 (en) 2021-09-02
HK1224341A1 (zh) 2017-08-18
ES2789580T3 (es) 2020-10-26
PT3719139T (pt) 2023-03-06
EP3029154B1 (en) 2017-10-04
PT3330383T (pt) 2020-05-06
SMT201600087B (it) 2016-07-01
EP3330383A1 (en) 2018-06-06
EP3029154A1 (en) 2016-06-08
EP2342360A4 (en) 2012-10-03
US9617583B2 (en) 2017-04-11
DK2342360T3 (en) 2016-04-11
HRP20171536T1 (hr) 2018-01-26
US10196677B2 (en) 2019-02-05

Similar Documents

Publication Publication Date Title
CY1119653T1 (el) Μεθοδος για ταυτοποιηση της ευαισθησιας ενος ασθενους σε θεραπεια αναστολης της τελομερασης
CY1118549T1 (el) Χρηση anti-vegf αντισωματος σε συνδυασμο με χημειοθεραπεια για τη θεραπευτικη αγωγη του καρκινου του μαστου
CY1118566T1 (el) Διαγνωση με χρηση ιντερφερονης τυπου 1
CY1123764T1 (el) Τετραϋδροβιοπτερινη για θεραπεια καταστασεων που σχετιζονται με αυξημενα επιπεδα φαινυλαλανινης
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1124281T1 (el) Θεραπευτικη χρηση ειδικου προσδετη σε σχετικες me msrv ασθενειες
CY1122428T1 (el) Θεραπευτικη αγωγη της παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας με διειδικα αντισωματα εναντι cd3xcd19
EA201490230A1 (ru) Применение меченых ингибиторов hsp90
CY1122557T1 (el) Μορια αντι-gcc αντισωματος και χρηση αυτων στη δοκιμη για επιδεκτικοτητα σε θεραπεια στοχευμενη σε gcc
CY1123051T1 (el) Ταπενταδολη για προληψη και θεραπεια καταθλιψης και αγχους
CY1110889T1 (el) C-αρυλο γλυκοζιτικοι sglt2 αναστολεις και μεθοδος για την παραγωγη τους
CY1118714T1 (el) Υψηλης συγγενειας ανθρωπινα αντισωματα κατα του ανθρωπινου ενεργοποιουμενου απο πρωτεαση υποδοχεα-2
EA201290846A1 (ru) Лучевая терапия, комбинированная с сенсибилизаторами гипоксической клетки
CY1118530T1 (el) Glyx-13 για χρηση σε μεθοδο θεραπευτικης αγωγης ανθεκτικης σε θεραπεια καταθλιψης
EA200701094A1 (ru) Усовершенствованное лечение рака с применением агонистов tlr3
EA201100335A8 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
MX2014016014A (es) Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon.
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
CY1116719T1 (el) Μεθοδοι ανιχνευσης αντισωματων αντι-φαρμακου
EA202090338A1 (ru) Функционально-модифицированные олигонуклеотиды и их субъединицы
CY1125948T1 (el) Σχημα αγωγης που χρησιμοποιει νερατινιμπη για τον καρκινο του μαστου
EA201590332A1 (ru) Фармацевтические комбинации, содержащие ингибитор b-raf, ингибитор egfr и, необязательно, ингибитор pi3k-альфа
CY1116823T1 (el) Στοχευση abcb5 για θεραπεια καρκινου
MX2019000425A (es) Terapia anti-angiogenesis para el tratamiento del cancer ovarico.
CY1110341T1 (el) Παραγωγα κιναζολινης και η χρηση τους στην θεραπευτικη αγωγη θρομβοκυτταραιμιας